RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
VBI Vaccines - Stock

VBI Vaccines P/S 2024

VBI Vaccines P/S

0.73

Ticker

VBIV

ISIN

CA91822J1030

WKN

A2AJ0L

As of Jun 24, 2024, VBI Vaccines's P/S ratio stood at 0.73, a -85.71% change from the 5.11 P/S ratio recorded in the previous year.

The VBI Vaccines P/S history

VBI Vaccines Aktienanalyse

What does VBI Vaccines do?

VBI Vaccines Inc is a company focused on the development and commercialization of vaccines. The company was founded in Canada in 2001 and is currently headquartered in Cambridge, Massachusetts, USA. Its business model is based on research, development, and marketing of vaccines for the prevention and treatment of infectious diseases. VBI Vaccines works closely with academic institutions, government agencies, biotech companies, and pharmaceutical companies to advance its products. The company offers a wide range of products, including prophylactic vaccines against infectious diseases such as Hepatitis B, Cytomegalovirus, Japanese encephalitis, and uncontrolled HIV infections. It is also working on the development of therapeutic vaccines against cancer. One of VBI Vaccines' key divisions is the hepatitis B vaccines, with its innovative platform called Sci-B-Vac offering higher protection and longer effectiveness than other available vaccines. VBI Vaccines has also developed a prophylactic platform called LPV™ technology (Lipid Particle Vaccine) which facilitates vaccine production by being easy to manufacture, stable, and transportable. This technology also allows for rapid development of vaccines against new infectious diseases. The company is also involved in the clinical development of therapeutic vaccines against cancer, aiming to mobilize and activate the body's immune system against cancer cells. Successful clinical studies have been conducted for therapy vaccines against glioblastomas (a type of brain tumor) and rhabdomyosarcomas (a rare tumor). Overall, VBI Vaccines has a promising research path for the development of vaccines for the prevention and treatment of infectious diseases and cancer. The company is innovative and relies on technologies that improve vaccine effectiveness and ease their production. VBI Vaccines ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding VBI Vaccines's P/S Ratio

VBI Vaccines's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing VBI Vaccines's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating VBI Vaccines's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in VBI Vaccines’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about VBI Vaccines Stock

What is the price-to-earnings ratio of VBI Vaccines?

The price-earnings ratio of VBI Vaccines is currently 0.73.

How has the price-earnings ratio of VBI Vaccines changed compared to last year?

The price-to-earnings ratio of VBI Vaccines has increased by -85.71% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of VBI Vaccines high compared to other companies?

Yes, the price-to-earnings ratio of VBI Vaccines is high compared to other companies.

How does an increase in the price-earnings ratio of VBI Vaccines affect the company?

An increase in the price-earnings ratio of VBI Vaccines would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of VBI Vaccines affect the company?

A decrease in the price-earnings ratio of VBI Vaccines would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of VBI Vaccines?

Some factors that influence the price-earnings ratio of VBI Vaccines are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does VBI Vaccines pay?

Over the past 12 months, VBI Vaccines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, VBI Vaccines is expected to pay a dividend of 0 USD.

What is the dividend yield of VBI Vaccines?

The current dividend yield of VBI Vaccines is .

When does VBI Vaccines pay dividends?

VBI Vaccines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of VBI Vaccines?

VBI Vaccines paid dividends every year for the past 0 years.

What is the dividend of VBI Vaccines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is VBI Vaccines located?

VBI Vaccines is assigned to the 'Health' sector.

Wann musste ich die Aktien von VBI Vaccines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VBI Vaccines from 6/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/24/2024.

When did VBI Vaccines pay the last dividend?

The last dividend was paid out on 6/24/2024.

What was the dividend of VBI Vaccines in the year 2023?

In the year 2023, VBI Vaccines distributed 0 USD as dividends.

In which currency does VBI Vaccines pay out the dividend?

The dividends of VBI Vaccines are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von VBI Vaccines

Our stock analysis for VBI Vaccines Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VBI Vaccines Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.